CU20210058A7 - Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden - Google Patents

Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Info

Publication number
CU20210058A7
CU20210058A7 CU2021000058A CU20210058A CU20210058A7 CU 20210058 A7 CU20210058 A7 CU 20210058A7 CU 2021000058 A CU2021000058 A CU 2021000058A CU 20210058 A CU20210058 A CU 20210058A CU 20210058 A7 CU20210058 A7 CU 20210058A7
Authority
CU
Cuba
Prior art keywords
seq
inhibit
linear peptides
compositions
mediated phosphorylation
Prior art date
Application number
CU2021000058A
Other languages
English (en)
Other versions
CU24766B1 (es
Inventor
Pérez Vladimir Armando Besada
Menéndez Evelín Caballero
Pérez Hilda Elisa Garay
Blanco Sonia Gonzalez
López Luis Javier González
Nieto Gerardo Enrique Guillén
González Yordanka Masforrol
Rodríguez Silvio Ernesto Perea
Negrín Yasser Perera
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2021000058A priority Critical patent/CU24766B1/es
Priority to ARP220101768A priority patent/AR126388A1/es
Priority to US18/578,001 priority patent/US20240317827A1/en
Priority to CA3225387A priority patent/CA3225387A1/en
Priority to JP2024514574A priority patent/JP2024534231A/ja
Priority to MX2024000542A priority patent/MX2024000542A/es
Priority to EP22760645.6A priority patent/EP4368710A1/en
Priority to KR1020247003121A priority patent/KR20240032882A/ko
Priority to CN202280055326.7A priority patent/CN117795064A/zh
Priority to AU2022308094A priority patent/AU2022308094A1/en
Priority to PCT/CU2022/050007 priority patent/WO2023280330A1/es
Publication of CU20210058A7 publication Critical patent/CU20210058A7/es
Publication of CU24766B1 publication Critical patent/CU24766B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

<p>Péptidos lineales que inhiben la fosforilación mediada por la enzima Caseína Kinasa 2 (CK2), que poseen una secuencia de aminoácidos que se selecciona del grupo compuesto por las secuencias identificadas como SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:50 Y SEQ ID NO:57 - SEQ ID NO:62, así como los polipéptidos que comprenden dichos péptidos y un péptido de penetración intracelular. Una composición farmacéutica que comprende al menos uno de esos péptidos o polipétidos lineales y un excipiente farmacéuticamente aceptable. </p>
CU2021000058A 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2 CU24766B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
ARP220101768A AR126388A1 (es) 2021-07-09 2022-07-06 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden
US18/578,001 US20240317827A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
CA3225387A CA3225387A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof
JP2024514574A JP2024534231A (ja) 2021-07-09 2022-07-07 Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物
MX2024000542A MX2024000542A (es) 2021-07-09 2022-07-07 Peptidos lineales que inhiben la fosforilacion mediada por ck2 y composiciones que los comprenden.
EP22760645.6A EP4368710A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
KR1020247003121A KR20240032882A (ko) 2021-07-09 2022-07-07 Ck2-매개 인산화를 억제하는 선형 펩타이드 및 이를 포함하는 조성물
CN202280055326.7A CN117795064A (zh) 2021-07-09 2022-07-07 抑制由ck2介导的磷酸化的线性肽和包含其的组合物
AU2022308094A AU2022308094A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2

Publications (2)

Publication Number Publication Date
CU20210058A7 true CU20210058A7 (es) 2023-02-13
CU24766B1 CU24766B1 (es) 2025-08-13

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2

Country Status (11)

Country Link
US (1) US20240317827A1 (es)
EP (1) EP4368710A1 (es)
JP (1) JP2024534231A (es)
KR (1) KR20240032882A (es)
CN (1) CN117795064A (es)
AR (1) AR126388A1 (es)
AU (1) AU2022308094A1 (es)
CA (1) CA3225387A1 (es)
CU (1) CU24766B1 (es)
MX (1) MX2024000542A (es)
WO (1) WO2023280330A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides

Also Published As

Publication number Publication date
CU24766B1 (es) 2025-08-13
WO2023280330A1 (es) 2023-01-12
JP2024534231A (ja) 2024-09-18
US20240317827A1 (en) 2024-09-26
KR20240032882A (ko) 2024-03-12
AU2022308094A1 (en) 2024-02-01
MX2024000542A (es) 2024-02-02
EP4368710A1 (en) 2024-05-15
AR126388A1 (es) 2023-10-11
CN117795064A (zh) 2024-03-29
CA3225387A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
MX2024015050A (es) L-asparaginasa modificada
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
MX389173B (es) Receptores de celulas t.
EP4272765A3 (en) Adeno-associated virus (aav) clade f vector and uses therefor
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
CL2023000752A1 (es) Composiciones y métodos para tratar la enfermedad celiaca
CO2020011027A2 (es) Análogos de compstatina y sus usos médicos
CU20210058A7 (es) Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden
MX2025002921A (es) Composiciones de péptidos y fragmentos de proteínas de fibroína
AR123189A1 (es) VACUNA DE SINUCLEÍNA a PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS
AR074388A1 (es) Un peptido inhibidor del factor de necrosis tumoral alfa, un proceso para la preparacion de dicho peptido y una composicion farmaceutica que comprende dicho peptido
AR134636A1 (es) Compuestos peptídicos híbridos que tienen un residuo de lisina modificado
MX2021009161A (es) Acidos nucleicos recombinantes que contienen secuencias promotoras de alfaherpesvirus.
CU20200110A7 (es) Péptidos para el tratamiento de infecciones respiratorias de origen viral
AR132194A1 (es) PROTEÍNAS DIRIGIDAS A Ab Y MÉTODOS DE USO
ZA202203140B (en) Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
AR134637A1 (es) Compuestos peptídicos híbridos que tienen un residuo de triptófano sustituido o un sustituyente terminal
AR130835A1 (es) Péptidos natriuréticos de acción prolongada y usos de estos
WO2021160234A3 (en) Antimicrobial peptides from medicinal leeches
AR132563A1 (es) Nanoestructuras de proteína gb de cmv estabilizadas por prefusión
CY1119215T1 (el) Πεπτιδικα αναλογα και συζευγματα αυτων
AR122306A1 (es) Variantes del cnp y sus conjugados